

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

The following potential equalities issues were identified at scoping:
--

- | |
|--|
| <ul style="list-style-type: none">• Male and female outcomes may vary and should be considered separately, if possible.• Nintedanib capsules contain gelatin which may not be acceptable to some religious groups. This may be an equalities consideration if nerandomilast contains gelatin. |
|--|

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

The committee will consider any relevant equalities issues in its deliberations.

As sex is a protected characteristic under the Equality Act 2010, it would not be appropriate for the committee to consider subgroup analyses based on sex alone.
--

If evidence allows, the committee may consider whether there are any subgroups for whom the clinical and cost-effectiveness of nerandomilast is expected to be different. The committee will be mindful of equality considerations when assessing subgroups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the scope. The committee will consider all relevant potential equality issues during the appraisal process.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were added

Approved by Associate Director: Emily Crowe...

Date: 02/12/2025